Future Market Insights (FMI) has recently published an exhaustive yet unbiased study on the global fiducial markers market elaborating on the vital dynamics responsible for shaping future growth trajectory for the forecast period ranging from 2020-2030.
According to the American Cancer Society, in 2019, approximately 174,650 men were diagnosed with prostate cancer, up by 6% from 2018. It is also the second leading cause of deaths among American men, with over 33,000 fatalities expected by 2020-end.
Therefore, manufacturers are likely to find immense opportunities with respect to introducing fiducial markers to aid in eradicating this deadly disease across potential regions. Recent research has paved the way for non-implantable fiducial markers using the cone-beam CT technology.
For more insights into the market, request a sample of this report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-12825
Key Takeaways
- Global fiducial markers market to reach US$ 258.8 Mn by 2030, expanding at over 8% CAGR
- Pure gold fiducial markers to capture lion’s share, expected to generated over 60% revenue by 2020-end
- By modality, photon treatment is expected to generate an absolute opportunity worth US$ 12 Mn through 2030
- Maximum uptake likely across the prostate cancer segment, accounting for over 7 out of 10 fiducial marker applications
- Radiotherapy centers to remain primary end-users of fiducial markers due to deployment of specialized cancer treatments
- Europe and North America to capture an impressive market share, East Asia following closely
global fiducial markers market. As cancer treatment acquires precedence, healthcare providers are making accommodations to address patients suffering from debilitating conditions. Consequently, the need for precision-based detection systems has aggrandized in recent months.
Amid strict hygiene and social distancing protocols, healthcare providers are conducting radiation and chemotherapy procedures, leading to increased uptake of fiducial markers. Moreover, to reduce infection risks, patients requiring immediate surgical care are attended to first while consultation for possible prevalence have been shifted to virtual platforms.
Ask An Analyst @
https://www.futuremarketinsights.com/ask-question/rep-gb-12825
Competitive Landscape
The global fiducial markers market comprises of the following prominent players: Eckert & Ziegler BEBIG, Innovative Oncology Solutions, Boston Scientific, IBA Dosimetry, Best Medical International, Inc., Carbon Medical Technologies, CIVCO, alphaXRT, Nanovi A/S, and Stellar Medical to name a few.
A combination of expansion strategies, ranging from new product launches to strategic collaborations and alliances and technological disruptions are employed by these manufacturers to stay afloat in this highly competitive environment.
Innovative Oncology Solutions, for instance, markets the FLEXIMARC G/T Specialty Fiducial Markers, consisting of two 1.2 mm x 3 mm gold nodes separated by a thin, medical grade titanium filament which is optimized for MRI visibility. This permits soft tissue to anchor the marker in place, reducing chances of migration.
With regard to technological advancements, IBA Dosimetry announced the launch of its myQA iON radiation therapy integrated quality assurance (QA) platform in 2019. This platform incorporates process automation, task-based workflows and PT machine log files to streamline cancer treatment procedures.
More Insights on FMI’s Fiducial Markers Market Report
Future Market Insights, in its new report, offers an unbiased analysis of the global fiducial markers market, analyzing historical demand from 2015-2019 and forecast statistics for 2020-2030. The study reveals growth projections on the fiducial markers market on the basis of product (polymer based markers, metal based markers, pure gold markers and liquid based markers), modality (photon therapy, proton therapy, tomotherapy and cyberknife), disease site (head & neck, breast, lung, abdomen, prostate, kidney, cervix or other gynecologic organs) and end-user (hospitals, cancer research institutes and radiotherapy centers) across seven prominent regions.
Request a Complete TOC of this Report with figures @
https://www.futuremarketinsights.com/toc/rep-gb-12825
Key Market Segments Covered in Fiducial Markers Industry Research
Product:
- Polymer Based Markers
- Metal Based Markers
- Pure Gold Markers
- Liquid Based Markers
Modality:
- Photon Therapy
- Proton Therapy
- Tomotherapy
- Cyberknife
Disease Site:
- Head & Neck
- Breast
- Lung
- Abdomen
- Prostate
- Kidney
- Cervix or other gynaecologic organs
End User:
- Hospitals
- Cancer Research Institutes
- Radiotherapy Centers
About Us
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs
